Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Recruiting × AML × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 155 Neoplasms 136 Leukemia, Myeloid, Acute 136 Neoplasm Metastasis 134 Breast Neoplasms 126 Colorectal Neoplasms 118 Recurrence 101 Ovarian Neoplasms 95 Pancreatic Neoplasms 82 Advanced Solid Tumor 76 Prostatic Neoplasms 71 Lung Neoplasms 69 Multiple Myeloma 68 Stomach Neoplasms 63 Squamous Cell Carcinoma of Head and Neck 63 Advanced Solid Tumors 63 Lymphoma, Non-Hodgkin 62 Carcinoma, Hepatocellular 57 Triple Negative Breast Neoplasms 56 Melanoma 55 Glioblastoma 53 Lymphoma 52 Lymphoma, B-Cell 51 Precursor Cell Lymphoblastic Leukemia-Lymphoma 49 Myelodysplastic Syndromes 49 Endometrial Neoplasms 49 Glioma 46 Hematologic Neoplasms 42 Lymphoma, Large B-Cell, Diffuse 40 Sarcoma 39

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06731699 2024-12-17

A Phase 1 Study of FD-001 in Recurrent /Refractory (R/R)AML/NHL/MM/MDS

Chengdu FenDi Pharmaceutical Co., Ltd.

Phase 1 Recruiting

AML

Data powered by HemOnc (CC BY 4.0) Colophon ⚡